Dr Steven Wood
Clinical Medicine, School of Medicine and Population Health
Senior Research Associate
s.l.wood@sheffield.ac.uk
+44 114 215 9200
+44 114 215 9200
The Medical School
Full contact details
Dr Steven Wood
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Journal articles
- Identification of proteins which regulate the metastatic spread of breast cancer downstream of TWIST1. Bone Reports, 16, 101362-101362.
- A review and comparison of error estimators for anisotropic mesh adaptation for flow simulations. Computers and Fluids, 234.
- Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 126(3), 419-429.
- Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. Journal of Bone Oncology, 29, 100375-100375.
- Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases. Bone Reports, 14, 100840-100840.
- “The use of bisphosphonates to treat skeletal complications in solid tumours”. Bone, 115907-115907.
- Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. View this article in WRRO
- 30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients. Annals of Oncology, 31, S26-S26.
- Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis. Journal of Urology, 202(6), 1101-1101.
- Dedicator of cytokinesis 4 : a potential prognostic and predictive biomarker within the metastatic spread of breast cancer to bone. Cancer Informatics, 18, 1-3. View this article in WRRO
- Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247(3), 381-391. View this article in WRRO
- Novel mediators of breast cancer bone metastasis—insights from studies of gene-regulation and the global proteome. Annals of Translational Medicine, 6(S1), S71-S71.
- Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene, 38, 1751-1763. View this article in WRRO
- CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
- An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis. PROTEOMICS - Clinical Applications, 9(5-6), 507-521.
- Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews, 41(4), 361-375.
- Assessment of the Impact of Targeted Therapy on Metastatic Bone Disease in Renal Cancer. European Urology, 66(3), 510-511.
- The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treatment Reviews, 40(4), 558-566.
- Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment. Cancer Treatment Reviews, 40(1), 139-152.
- Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney International, 84(6), 1214-1225.
- Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nature Reviews Urology, 10(4), 206-218.
- Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treatment Reviews, 38(4), 284-291.
- Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. British Journal of Cancer, 103(1), 101-111.
- Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 12(8), 2109-2109.
Chapters
- Identification of new therapeutic targets of bone cancers by proteomic strategies, Bone Cancer (pp. 783-803). Elsevier
- TKIs in Renal Cell Carcinoma, Oncogenomics (pp. 551-563). Elsevier
- List of Contributors, Oncogenomics (pp. xv-xx). Elsevier
- Bone Metastases; Clinical Aspects In Martini L & Huhtaniemi I (Ed.), Encyclopedia of Endocrine Diseases (pp. 310-319). Oxford: Elsevier. View this article in WRRO
- Bone Metastases; Clinical Aspects, Encyclopedia of Endocrine Diseases (pp. 310-319). Elsevier
- TKIs in renal cell carcinoma: What can we expect in the future?, Oncogenomics: From Basic Research to Precision Medicine (pp. 551-563). View this article in WRRO
- The Application of ‘Omics’ Techniques for Cancers That Metastasise to Bone: From Biological Mechanism to Biomarkers In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases (pp. 125-153). Springer Netherlands
Conference proceedings papers
- Development of a targeted strategy for enrichment and detection of calcium-binding proteins as potential biomarkers for bone metastases in breast cancer. Bone, Vol. 48(1) (pp S50-S51)
- Identification of proteins which regulate the metastatic spread of breast cancer downstream of TWIST1. Bone Reports, 16, 101362-101362.